Academic Journal
Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets.
| Τίτλος: | Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets. |
|---|---|
| Συγγραφείς: | Tan SK; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA.; Sheila and David Fuente Graduate Program in Cancer Biology, University of Miami Miller School of Medicine, Miami, FL, USA., Hougen HY; Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA., Merchan JR; Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Gonzalgo ML; Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA.; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA., Welford SM; Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA. Scott.welford@med.miami.edu.; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. Scott.welford@med.miami.edu. |
| Πηγή: | Nature reviews. Urology [Nat Rev Urol] 2023 Jan; Vol. 20 (1), pp. 48-60. Date of Electronic Publication: 2022 Oct 03. |
| Τύπος έκδοσης: | Journal Article; Review; Research Support, N.I.H., Extramural |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500082 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-4820 (Electronic) Linking ISSN: 17594812 NLM ISO Abbreviation: Nat Rev Urol Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : Nature Pub. Group |
| Ιατρικοί όροι (MeSH): | Carcinoma, Renal Cell*/pathology , Kidney Neoplasms*/pathology, Lipid Metabolism/genetics ; Fatty Acids/metabolism ; Humans ; Lipids |
| Περίληψη: | Lipid droplet formation is a defining histological feature in clear-cell renal cell carcinoma (ccRCC) but the underlying mechanisms and importance of this biological behaviour have remained enigmatic. De novo fatty acid (FA) synthesis, uptake and suppression of FA oxidation have all been shown to contribute to lipid storage, which is a necessary tumour adaptation rather than a bystander effect. Clinical studies and mechanistic investigations into the roles of different enzymes in FA metabolism pathways have revealed new metabolic vulnerabilities that hold promise for clinical effect. Several metabolic alterations are associated with worse clinical outcomes in patients with ccRCC, as lipogenic genes drive tumorigenesis. Enzymes involved in the intrinsic FA metabolism pathway include FA synthase, acetyl-CoA carboxylase, ATP citrate lyase, stearoyl-CoA desaturase 1, cluster of differentiation 36, carnitine palmitoyltransferase 1A and the perilipin family, and each might be potential therapeutic targets in ccRCC owing to the link between lipid deposition and ccRCC risk. Adipokines and lipid species are potential biomarkers for diagnosis and treatment monitoring in patients with ccRCC. FA metabolism could potentially be targeted for therapeutic intervention in ccRCC as small-molecule inhibitors targeting the pathway have shown promising results in preclinical models. (© 2022. Springer Nature Limited.) |
| References: | J Lipid Res. 1995 Jun;36(6):1211-26. (PMID: 7665999) Clin Cancer Res. 2003 Nov 15;9(15):5699-704. (PMID: 14654554) J Immunol. 2016 Jul 15;197(2):611-9. (PMID: 27316682) PLoS One. 2017 Feb 8;12(2):e0171615. (PMID: 28178338) Can Urol Assoc J. 2011 Aug;5(4):274-82. (PMID: 21801687) Mol Med Rep. 2014 Jun;9(6):2251-6. (PMID: 24691570) Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83. (PMID: 10092513) Cell Death Dis. 2021 Oct 21;12(11):977. (PMID: 34675185) Urol Oncol. 2018 Jul;36(7):343.e9-343.e19. (PMID: 29773494) N Engl J Med. 2015 Nov 5;373(19):1814-23. (PMID: 26406150) Biomarkers. 2019 Sep;24(6):607-614. (PMID: 31215811) Cureus. 2020 Dec 19;12(12):e12178. (PMID: 33489589) Adv Drug Deliv Rev. 2020;159:245-293. (PMID: 32711004) Front Cell Dev Biol. 2021 Sep 23;9:668810. (PMID: 34631694) J Proteome Res. 2021 Jan 1;20(1):841-857. (PMID: 33207877) J Cancer. 2019 Oct 21;10(26):6599-6607. (PMID: 31777589) Biochem Biophys Res Commun. 2003 Mar 21;302(4):898-903. (PMID: 12646257) Arch Biochem Biophys. 1969 Dec;135(1):209-17. (PMID: 5362924) JHEP Rep. 2021 Jan 28;3(3):100237. (PMID: 34151243) Int J Cancer. 2007 Apr 1;120(7):1573-8. (PMID: 17205522) J Clin Invest. 1977 Jul;60(1):265-70. (PMID: 874089) Comput Math Methods Med. 2022 May 10;2022:1466991. (PMID: 35592685) Science. 2015 Jan 23;347(6220):1260419. (PMID: 25613900) Anticancer Res. 2009 Jun;29(6):2243-52. (PMID: 19528489) Cancer Discov. 2015 Jun;5(6):652-67. (PMID: 25829424) Nat Commun. 2017 Nov 24;8(1):1769. (PMID: 29176561) Antioxid Redox Signal. 2016 Aug 20;25(6):300-25. (PMID: 27353526) Cell Chem Biol. 2017 Dec 21;24(12):1445-1454.e8. (PMID: 29033315) Carcinogenesis. 2019 Oct 16;40(10):1191-1197. (PMID: 31001636) Sci Transl Med. 2019 Feb 6;11(478):. (PMID: 30728288) Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230) Cancer Res. 2008 Oct 15;68(20):8547-54. (PMID: 18922930) Int J Oncol. 2018 Jul;53(1):137-147. (PMID: 29749470) Nat Commun. 2019 Apr 8;10(1):1617. (PMID: 30962421) Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10715-20. (PMID: 15235125) J Lipid Res. 2004 Jun;45(6):1030-9. (PMID: 14993240) Nature. 2011 Nov 20;481(7381):380-4. (PMID: 22101433) Oncol Lett. 2018 May;15(5):6967-6974. (PMID: 29725424) Sci Transl Med. 2011 Feb 9;3(69):69ra12. (PMID: 21307302) Hormones (Athens). 2009 Jan-Mar;8(1):39-46. (PMID: 19278051) Lipids Health Dis. 2017 Apr 28;16(1):83. (PMID: 28454542) Cancer Sci. 2013 Apr;104(4):416-22. (PMID: 23331615) Front Immunol. 2021 Mar 04;12:653358. (PMID: 33746989) J Natl Cancer Inst. 2012 Mar 7;104(5):415-20. (PMID: 22312135) Trends Cancer. 2020 Jun;6(6):448-450. (PMID: 32459999) Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):680s-684s. (PMID: 17255293) Ital J Biochem. 2004 Dec;53(4):169-82. (PMID: 15997910) Cancer Cell. 2008 Dec 9;14(6):435-46. (PMID: 19061835) Cancer Discov. 2019 Mar;9(3):416-435. (PMID: 30626590) Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):66-71. (PMID: 11756683) JAMA Oncol. 2021 May 1;7(5):773-775. (PMID: 33662110) Nature. 2016 Nov 3;539(7627):112-117. (PMID: 27595394) Cancer Discov. 2021 Dec 1;11(12):3106-3125. (PMID: 34244212) Mol Cell. 2008 May 23;30(4):393-402. (PMID: 18498744) Theranostics. 2019 Jul 9;9(18):5359-5373. (PMID: 31410220) J Clin Oncol. 2016 Oct 20;34(30):3655-3663. (PMID: 27601543) J Clin Invest. 2002 Oct;110(8):1093-103. (PMID: 12393845) Urol Oncol. 2017 Nov;35(11):661.e1-661.e6. (PMID: 28797586) Urol Oncol. 2013 Feb;31(2):264-70. (PMID: 21676631) Int J Genomics. 2020 Aug 17;2020:9493256. (PMID: 33381539) Theranostics. 2019 Jul 9;9(17):4893-4908. (PMID: 31410189) Am J Physiol. 1984 Jul;247(1 Pt 2):R146-53. (PMID: 6742224) J Cell Biochem. 2014 Jun;115(6):1147-58. (PMID: 24402912) Urology. 2005 Jun;65(6):1168-72. (PMID: 15922427) Int J Biol Markers. 2019 Jun;34(2):168-175. (PMID: 30912469) Cancer Res. 1953 Jan;13(1):27-9. (PMID: 13032945) J Exp Med. 2003 Oct 6;198(7):977-85. (PMID: 14530373) Cancers (Basel). 2019 Jul 05;11(7):. (PMID: 31284458) Eur J Endocrinol. 2009 Aug;161(2):339-44. (PMID: 19497986) J Biol Chem. 2007 Sep 21;282(38):28175-88. (PMID: 17635925) J Biol Chem. 2000 Oct 20;275(42):32523-9. (PMID: 10913136) Metabolism. 2020 Sep;110:154302. (PMID: 32589900) Lancet. 2008 Feb 16;371(9612):569-78. (PMID: 18280327) Front Oncol. 2021 Sep 15;11:727778. (PMID: 34604067) Cancer Res. 2020 Jan 15;80(2):319-333. (PMID: 31690668) Clin Exp Pharmacol Physiol. 2021 Dec;48(12):1579-1588. (PMID: 34314523) J Am Soc Nephrol. 2018 Jan;29(1):81-91. (PMID: 28993506) Oncotarget. 2015 Mar 30;6(9):7348-63. (PMID: 25749516) Mol Nutr Food Res. 2019 Oct;63(20):e1900183. (PMID: 31325205) J Natl Cancer Inst. 2013 Dec 18;105(24):1862-70. (PMID: 24285872) J Neurosurg Sci. 1992 Jan-Mar;36(1):11-25. (PMID: 1323645) Bioorg Med Chem. 2017 Jul 15;25(14):3768-3779. (PMID: 28571972) Lancet Oncol. 2020 Feb;21(2):283-293. (PMID: 31870811) Front Oncol. 2019 Jul 18;9:596. (PMID: 31380268) Antioxid Redox Signal. 2006 Jul-Aug;8(7-8):1249-52. (PMID: 16910772) Metabolites. 2021 Nov 09;11(11):. (PMID: 34822423) Proc Natl Acad Sci U S A. 2021 Jun 15;118(24):. (PMID: 34099557) Dis Markers. 2019 Apr 4;2019:5702026. (PMID: 31089396) N Engl J Med. 2021 Nov 25;385(22):2036-2046. (PMID: 34818478) PLoS One. 2016 Nov 18;11(11):e0166231. (PMID: 27861513) Cancer Cell. 2015 Jan 12;27(1):57-71. (PMID: 25584894) Pathol Res Pract. 2020 Nov;216(11):153227. (PMID: 33027752) Cancer Biomark. 2010;9(1-6):461-73. (PMID: 22112490) J Cancer Res Ther. 2018;14(4):873-880. (PMID: 29970669) Cancer Discov. 2021 Aug;11(8):2072-2093. (PMID: 33757970) Nature. 2021 Nov;599(7885):485-490. (PMID: 34759321) Med Hypotheses. 2019 Aug;129:109239. (PMID: 31371068) Cold Spring Harb Symp Quant Biol. 2016;81:93-103. (PMID: 28062532) Urol Oncol. 2015 Feb;33(2):67.e15-23. (PMID: 25153774) Lipids Health Dis. 2019 May 24;18(1):118. (PMID: 31122252) Science. 2006 Mar 3;311(5765):1258-62. (PMID: 16513975) Front Biosci (Schol Ed). 2010 Jan 01;2(2):515-26. (PMID: 20036965) Eur Urol. 2008 Oct;54(4):866-73. (PMID: 18343565) Br J Cancer. 2020 Jan;122(1):4-22. (PMID: 31819192) Nat Rev Urol. 2010 May;7(5):245-57. (PMID: 20448658) PLoS One. 2013 Oct 22;8(10):e78250. (PMID: 24167613) Oncogenesis. 2017 Feb 27;6(2):e299. (PMID: 28240737) J Med Chem. 2011 Jul 28;54(14):5082-96. (PMID: 21661758) Stem Cells. 2014 Jul;32(7):1746-58. (PMID: 24737733) Int J Cancer. 2013 Feb 1;132(3):625-34. (PMID: 22610826) Eur Urol Oncol. 2019 Nov;2(6):643-648. (PMID: 31411994) Arterioscler Thromb Vasc Biol. 2018 May;38(5):1178-1190. (PMID: 29449335) Int J Mol Sci. 2016 Nov 09;17(11):. (PMID: 27834856) Urol Oncol. 2016 Jun;34(6):259.e15-9. (PMID: 26992934) Transl Androl Urol. 2019 May;8(Suppl 2):S138-S146. (PMID: 31236331) J Biol Chem. 2000 Dec 8;275(49):38486-93. (PMID: 10948207) Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):29-33. (PMID: 14551151) Carcinogenesis. 2013 Jan;34(1):109-12. (PMID: 23042303) Oncogene. 2018 Oct;37(40):5435-5450. (PMID: 29872221) Cancer Metab. 2016 Apr 01;4:6. (PMID: 27042297) J Biol Chem. 2003 Sep 26;278(39):37713-21. (PMID: 12840023) Metabolites. 2020 Dec 13;10(12):. (PMID: 33322148) Physiol Res. 2006;55(3):233-244. (PMID: 16238454) Int J Cancer. 2006 Feb 1;118(3):728-38. (PMID: 16094628) Oncotarget. 2017 Apr 25;8(17):29487-29500. (PMID: 28412757) Nature. 2013 Jul 4;499(7456):43-9. (PMID: 23792563) Cancer Lett. 2018 Dec 1;438:76-85. (PMID: 30213558) Cancer Res. 2012 Aug 1;72(15):3709-14. (PMID: 22787121) J Urol. 2008 Aug;180(2):729-36. (PMID: 18555493) Cancers (Basel). 2019 Dec 13;11(12):. (PMID: 31847105) J Biol Chem. 2005 Dec 30;280(52):42841-7. (PMID: 16115879) Nat Rev Cancer. 2007 Oct;7(10):763-77. (PMID: 17882277) JAMA Netw Open. 2021 Mar 1;4(3):e213520. (PMID: 33779745) J Gastrointest Cancer. 2012 Sep;43(3):508-11. (PMID: 21727995) Cancer Res. 2000 Jan 15;60(2):213-8. (PMID: 10667561) Arterioscler Thromb Vasc Biol. 2003 Mar 1;23(3):434-9. (PMID: 12615693) Prostate. 2001 May 1;47(2):102-10. (PMID: 11340632) Nat Rev Immunol. 2011 Feb;11(2):85-97. (PMID: 21252989) Circ Res. 1988 Dec;63(6):1036-43. (PMID: 3197271) Cancer Lett. 2017 Jan 1;384:39-49. (PMID: 27693630) Sci Transl Med. 2016 Mar 9;8(329):329ra34. (PMID: 26962158) J Urol. 2008 Sep;180(3):1137-40. (PMID: 18639282) Cell Metab. 2018 Jul 03;28(1):104-117.e5. (PMID: 29861385) Ann Surg Oncol. 2020 Jul;27(7):2459-2467. (PMID: 32246312) Sci Rep. 2017 Feb 20;7:42574. (PMID: 28218306) Nature. 1994 Dec 1;372(6505):425-32. (PMID: 7984236) Cell. 2017 Oct 5;171(2):273-285. (PMID: 28985560) N Engl J Med. 2000 Nov 2;343(18):1305-11. (PMID: 11058675) Cell Stem Cell. 2017 Mar 2;20(3):303-314.e5. (PMID: 28041894) J Biol Chem. 2011 Jul 22;286(29):25655-62. (PMID: 21622568) Ann Thorac Surg. 2002 May;73(5):1567-71. (PMID: 12022551) Cancer Discov. 2019 Aug;9(8):1006-1021. (PMID: 31088840) J Cell Commun Signal. 2018 Mar;12(1):91-101. (PMID: 28735362) Nature. 2017 Jan 5;541(7635):41-45. (PMID: 27974793) Breast Cancer Res Treat. 2013 Jan;137(1):319-27. (PMID: 23208590) EBioMedicine. 2022 May;79:104001. (PMID: 35439677) J Biol Chem. 2009 Sep 25;284(39):26695-707. (PMID: 19640849) J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94. (PMID: 16288122) J Biol Chem. 1990 Jan 25;265(3):1502-9. (PMID: 1967254) EClinicalMedicine. 2021 Mar 30;34:100797. (PMID: 33870151) Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1595-9. (PMID: 10845877) Mamm Genome. 2001 Sep;12(9):741-9. (PMID: 11641724) Oncol Lett. 2020 Nov;20(5):165. (PMID: 32952654) Nat Rev Cancer. 2019 Nov;19(11):651-661. (PMID: 31530936) Cell Metab. 2013 Mar 5;17(3):372-85. (PMID: 23473032) Transl Oncol. 2020 Feb;13(2):177-185. (PMID: 31865180) Mol Cell Biol. 2005 Jul;25(13):5675-86. (PMID: 15964822) J Clin Oncol. 2006 Jan 1;24(1):16-24. (PMID: 16330672) Nat Rev Nephrol. 2020 May;16(5):253-254. (PMID: 32123371) Cell. 2020 Apr 30;181(3):716-727.e11. (PMID: 32259488) Neoplasia. 2019 Sep;21(9):921-931. (PMID: 31401413) Cancer Immunol Immunother. 2019 Dec;68(12):2005-2014. (PMID: 31701161) Clin Cancer Res. 2003 Jun;9(6):2204-12. (PMID: 12796387) Oncotarget. 2014 Oct 15;5(19):9362-81. (PMID: 25313139) J Biol Chem. 2010 Aug 27;285(35):27418-27428. (PMID: 20558738) J Am Soc Nephrol. 2018 Sep;29(9):2326-2336. (PMID: 29976587) Trends Cancer. 2019 Nov;5(11):693-703. (PMID: 31735288) Int Urol Nephrol. 2017 Jun;49(6):975-981. (PMID: 28271326) Oncogene. 2005 Sep 15;24(41):6314-22. (PMID: 16007201) J Genet Genomics. 2015 Jul 20;42(7):343-53. (PMID: 26233890) J Lipid Res. 1997 Nov;38(11):2249-63. (PMID: 9392423) Biochem J. 1990 Nov 15;272(1):181-6. (PMID: 2176080) Cancer Metab. 2016 Jul 13;4:14. (PMID: 27418963) Mol Microbiol. 2007 Nov;66(4):829-39. (PMID: 17919287) Nat Methods. 2013 Nov;10(11):1046-7. (PMID: 24037243) Eur Urol Focus. 2016 Jun;2(2):197-203. (PMID: 28723535) Kardiol Pol. 2019;77(2):207-216. (PMID: 30740643) Oncotarget. 2017 Oct 6;9(1):3-20. (PMID: 29416592) Nature. 2021 May;593(7858):282-288. (PMID: 33828302) Nat Metab. 2021 Mar;3(3):327-336. (PMID: 33758423) Cell Death Differ. 2018 Mar;25(3):486-541. (PMID: 29362479) Lipids Health Dis. 2011 Oct 12;10:176. (PMID: 21988829) Evid Based Complement Alternat Med. 2012;2012:197920. (PMID: 22924054) Biomed Pharmacother. 2021 Jun;138:111454. (PMID: 33714781) J Biol Chem. 1993 Aug 25;268(24):17665-8. (PMID: 7688729) Cell. 2018 Apr 5;173(2):338-354.e15. (PMID: 29625051) Trends Cancer. 2016 Dec;2(12):758-770. (PMID: 28741521) J Clin Invest. 2002 Dec;110(11):1687-93. (PMID: 12464674) J Exp Clin Cancer Res. 2019 Feb 4;38(1):52. (PMID: 30717785) PLoS One. 2013;8(3):e59796. (PMID: 23536888) J Cancer. 2018 Jun 23;9(15):2734-2742. (PMID: 30087714) Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81. (PMID: 14983034) Sci Adv. 2016 May 27;2(5):e1600200. (PMID: 27386546) Annu Rev Nutr. 2014;34:281-303. (PMID: 24850384) Oncotarget. 2019 Mar 1;10(18):1688-1703. (PMID: 30899441) J Biol Chem. 2000 Jan 7;275(1):223-8. (PMID: 10617608) Cancer Cell. 2007 Apr;11(4):335-47. (PMID: 17418410) Clin Cancer Res. 2013 May 1;19(9):2368-80. (PMID: 23633458) Nat Struct Mol Biol. 2005 Mar;12(3):225-32. (PMID: 15711565) Oncotarget. 2016 Jun 28;7(26):39970-39979. (PMID: 27223066) J Cancer. 2019 Jul 25;10(19):4522-4531. (PMID: 31528216) J Exp Clin Cancer Res. 2017 May 12;36(1):66. (PMID: 28494778) |
| Grant Information: | R01 CA254409 United States CA NCI NIH HHS |
| Substance Nomenclature: | 0 (Fatty Acids) 0 (Lipids) |
| Entry Date(s): | Date Created: 20221003 Date Completed: 20230110 Latest Revision: 20241023 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10826284 |
| DOI: | 10.1038/s41585-022-00654-6 |
| PMID: | 36192502 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1759-4820 |
|---|---|
| DOI: | 10.1038/s41585-022-00654-6 |